Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Deciphering Heterogeneity: The Good, The Bad and The Different

Four online seminars launched by the University of Arizona College of Pharmacy are aimed at helping health care decision-makers understand how heterogeneity, or individual treatment effects, impact patient health outcomes.

The seminars are particularly relevant given the growing interest in comparative effectiveness research (CER), which can be very useful in helping patients and their health care providers make informed decisions about their treatment options. The challenge, however, is in figuring out whether the information will apply to an individual patient who might respond differently to that treatment. That’s because most CER studies examine how an “average” patient will respond to a treatment, leaving some patients wondering about whether CER findings will apply to them.

To address these concerns, the seminars explain how to evaluate CER findings for heterogeneity, the implications of applying “average” effects to individual patients or groups, and how heterogeneity influences patient outcomes. The seminars are geared toward medical and pharmacy directors, pharmacy managers, clinical support pharmacists, and clinicians.

The presentations include:

The seminars were developed by the Comparative Effectiveness Research Group at the University of Arizona College of Pharmacy with funding from the National Pharmaceutical Council.

In addition to the four seminars, the University of Arizona College of Pharmacy CER Group website features other heterogeneity tools and resources. These materials include two downloadable checklists, one to assess heterogeneity within a study, and another to assess heterogeneity across different studies, along with links to related websites and videos.

Blog Post

#TBT: 5 Years Later—Comparative Effectiveness Research Survey & the ACA

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Press Release

NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making

(Washington, DC, March 26, 2015)—A new survey of health care stakeholders reveals continued optimism that comparative effectiveness research (CER)...
Blog Post

CER Tweets of the Week: Upcoming Webinar on CER & the Environment for Health Care Decision-Making; PCORI Workshop on MS (March 16-20)

This week, comparative effectiveness research (CER) stakeholders shared invitations to register for the National Pharmaceutical Council’s (@npcnow)...
Press Release

NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making

(Washington, DC, March 26, 2015)—A new survey of health care stakeholders reveals continued optimism that comparative effectiveness research (CER)...
Press Release

Michael Ciarametaro Joins National Pharmaceutical Council as Director of Research

Washington, DC (July 31, 2014)—The National Pharmaceutical Council (NPC) today announced that Michael Ciarametaro has joined the health policy...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

NPC Annual Stakeholder Survey: Comparative Effectiveness Research Is Important, But Impact on Health Care Decision-Making Is Still on the Horizon

(Washington, DC, May 19, 2014)—A new survey of health care stakeholders reveals continued optimism for the use of comparative effectiveness research...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
YouTube Videos

CER and the Environment for Health Care Decision-Making

The National Pharmaceutical Council’s (NPC) fourth annual survey of health care stakeholders is continuing to shed light on the current environment...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
Blog Post

#TBT: 5 Years Later—Comparative Effectiveness Research Survey & the ACA

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

CER Tweets of the Week: Upcoming Webinar on CER & the Environment for Health Care Decision-Making; PCORI Workshop on MS (March 16-20)

This week, comparative effectiveness research (CER) stakeholders shared invitations to register for the National Pharmaceutical Council’s (@npcnow)...
Blog Post

CER Tweets of the Week: Comments on GAO’s PCORI Assessment, AHRQ Shared Decision-Making Webinar, BMJ on Negative Findings (March 9-13)

This week, comparative effectiveness research (CER) stakeholders tweeted comments in response to the U.S. Government Accountability Office’s (@USGAO...
Blog Post

CER Tweets of the Week: JCER on Relative Effectiveness Evidence; PCORI’s PCSI; GAO on AHRQ (March 2-6)

This week, comparative effectiveness research (CER) stakeholders tweeted about a series of articles published in the Journal of Comparative...
cersurvey-15

2015 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's fifth annual survey, "Comparative Effectiveness Research (CER) and the Environment for Health...

Exploration of Heterogeneity in Distributed Research Network Drug Safety Analyses

Distributed data network drug safety analyses are di

  •  
  • 1 of 15
  • >